Neurology
-
Randomized Controlled Trial
Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses.
To investigate the effects of siponimod on cognitive processing speed in patients with secondary progressive (SP) multiple sclerosis (MS), by means of a predefined exploratory and post hoc analysis of the Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) study, a randomized controlled trial comparing siponimod and placebo. ⋯ This study provides Class II evidence that, for patients with SPMS, siponimod had a significant benefit on cognitive processing speed.
-
Randomized Controlled Trial Multicenter Study
Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study.
To assess the long-term safety, tolerability, and efficacy of fremanezumab, a fully humanized monoclonal antibody approved for the preventive treatment of migraine. ⋯ This study provides Class IV evidence that long-term fremanezumab treatment is safe, well tolerated, and effective at sustaining reductions in monthly migraine and headache days.
-
Randomized Controlled Trial
Effects of home-based telerehabilitation in patients with stroke: A randomized controlled trial.
To determine the effects of a 12-week home-based motor training telerehabilitation program in patients with subcortical stroke by combining motor function assessments and multimodality MRI analysis methods. ⋯ This study provides Class II evidence that for patients with stroke with hemiplegia, home-based telerehabilitation compared to conventional rehabilitation significantly improves some motor function tests.
-
Randomized Controlled Trial Multicenter Study
One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study.
To assess efficacy and tolerability of 1-year erenumab treatment in patients with episodic migraine. ⋯ Class II evidence that 52 weeks of treatment with erenumab 70 and 140 mg subcutaneously monthly results in sustained reductions in monthly migraine days and similar dose tolerability for patients with episodic migraine.
-
Randomized Controlled Trial
Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline.
To determine the effect of low-dose aspirin vs placebo on incident all-cause dementia, incident Alzheimer disease (AD), mild cognitive impairment (MCI), and cognitive decline in older individuals. ⋯ NCT01038583.